· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2023 / N 1 Возможности апиксабана в лечении и профилактике рецидивов онкоассоциированных тромбозов О.В. Сомонова, А.Л. Елизарова Список литературы/References 1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Thrombosis and Haemostasis. 2014;112:843-852. DOI: 10.1160/TH14-08-0671 2. Fernandes CJCDS, Jardim CVP, Alves JL Jr, Oleas FAG, Morinaga LTK, Souza R. Reperfusion in acute pulmonary thromboembolism. Jornal Brasileiro de Pneumologia. 2018;44(3):237-243. DOI: 10.1590/S1806-37562017000000204 3. Ogren M, Bergqvist D, Wåhlander K, Eriksson H, Sternby NH. Trousseau’s syndrome – what is the evidence? A population-based autopsy study. Thrombosis and Haemostasis. 2006;95(3):541-545. DOI: 10.1160/TH05-10-0694 4. Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Practice & Research. Clinical Haematology. 2009;22(1):9-23. DOI: 10.1016/j.beha.2008.12.001 5. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, Ten Cate-Hoek AJ, Elalamy I, Enzmann FK, Geroulakos G, Gottsäter A, Hunt BJ, Mansilha A, Nicolaides AN, Sandset PM, Stansby G, Esvs Guidelines Committee, de Borst GJ, Bastos Gonçalves F, Chakfé N, Hinchliffe R, Kolh P, Koncar I, Lindholt JS, Tulamo R, Twine CP, Vermassen F, Wanhainen A, Document Reviewers, De Maeseneer MG, Comerota AJ, Gloviczki P, Kruip MJHA, Monreal M, Prandoni P, Vega de Ceniga M. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. European Journal of Vascular and Endovascular Surgery. 2021;61(1):9-82. DOI: 10.1016/j.ejvs.2020.09.023 6. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. Journal of Cardiology. 2018;72(2):89-93. DOI: 10.1016/j.jjcc.2018.02.011 7. ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiology of Haemostasis and Thrombosis. 2008;36(3-4):122-130. DOI: 10.1159/000175150 8. Agnelii G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thrombosis Research. 2010;125(Suppl. 2):S17-S20. DOI: 10.1016/S0049-3848(10)70007-4 9. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancer. Archives of Internal Medicine. 2006;166(4):458-464. DOI:10.1001/archinte.166.4.458 10. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Annals of Surgery. 2006;243(1):89-95. DOI: 10.1097/01.sla.0000193959.44677.48 11. Nalluri SR, Chu D, Keresztes R, Zhou X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-2285. DOI:10.1001/jama.2008.656 12. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prevention Research (Philadelphia, Pa.). 2010;3(6):696-706. DOI:10.1158/1940-6207.CAPR-10-0076 13. Khorana AA, DeSancho MT, Liebman H, Rosovsky R, Connors JM, Zwicker J. Prediction and prevention of cancer-associated thromboembolism. The Oncologist. 2021;26(1):2-e7. DOI: 10.1002onco.13569 14. Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CVP, Souza R. Cancer-associated thrombosis: the when, how and why. European Respiratory Review. 2019;28(151):180119. DOI: 10.1183/16000617.0119-2018 15. Watson HG, Keeling DM, Laffan M, Tait RC, Makris M; British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. British Journal of Haematology. 2015;170(5):640-648. DOI: 10.1111/bjh.13556 16. Khorana A, Carrier M, Garcia D, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2016;41(1):81-91. DOI: 10.1007/s11239-015-1313-4 17. Mir Seyed Nazari P, Riedl J, Pabinger I, Ay C. The role of pododlanin in cancer-associated thrombosis. Thrombosis Research. 2018;164(Suppl. 1):S34-S39. DOI: 10.1016/j.thromres.2018.01.020 18. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: Chest guideline and Expert Panel report. Chest. 2016;149(2):315-352. DOI: 10.1016/j.chest.2015.11.026 19. Khorana AA, Yannicelli D, McGrae KR, Milentijevic D, Crivera C, Nelson WW, Schein JR. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thrombosis Research. 2016;145:51-53. DOI: 10.1016/j.thromres.2016.07.013 20. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. Journal of Clinical Oncology. 2020;38(5):496-520. DOI: 10.1200/JCO.19.01461 21. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. The Lancet. Oncology. 2022;23(7):e334-e347. DOI: 10.1016/S1470-2045(22)00160-7 22. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine. 2013;369(9):799-808. DOI: 10.1056/NEJMoa1302507 23. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis. 2015;13(12):2187-2191. DOI: 10.1111/jth.13153 24. Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, Vo L, Mardekian J, Pan X, Burns L, Atwood M, Hanau A, Cohen AT. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thrombosis and Haemostasis. 2018;118(11):1951-1961. DOI: 10.1055/s-0038-1673689 25. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. Journal of Thrombosis and Haemostasis. 2020;18(2):411-421. DOI: 10.1111/jth.14662 26. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, Becattini C, Agnelli G. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis. 2021;121(5):616-624. DOI: 10.1055/s-0040-1720975 27. Giustozzi M, Connors JM, Ruperez Blanco AB, Szmit S, Falvo N, Cohen AT, Huisman M, Bauersachs R, Dentali F, Becattini C, Agnelli G. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Hemostasis. 2021;19(11):2751-2759. DOI: 10.1111/jth.15461 28. Verso M, Munoz A, Bauersachs R, Huisman MV, Mandalà M, Vescovo G, Becattini C, Agnelli G. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer (Oxford, England: 1990). 2021;148:371-381. DOI: 10.1016/j.ejca.2021.02.026 29. Agnelli G, Muñoz A, Franco L, Mahé I, Brenner B, Connors JM, Gussoni G, Hamulyak EN, Lambert C, Suero MR, Bauersachs R, Torbicki A, Becattini C. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis. 2022 May;122(5):796-807. DOI: 10.1055/s-0041-1735194 30. Becattini C, Bauersachs R, Maraziti G, Bertoletti L, Cohen A, Connors JM, Manfellotto D, Sanchez A, Brenner B, Agnelli G. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica. 2022;107(7):1567-1576. DOI: 10.3324/haematol.279072 31. Mokadem ME, Hassan A, Algaby AZ. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular. 2021;29(5):745-750. DOI: 10.1177/1708538120971148 32. Мареев В.Ю., Мареев Ю.В. Роль антикоагулянтов в лечении и профилактике рецидивов венозных тромбоэмболических осложнений у пациентов со злокачественными новообразованиями: мета-анализ рандомизированных исследований с апиксабаном. Кардиология. 2022;62(3):4-15. [Mareyev VYu, Mareyev YuV. Role of anticoagulants in therapy and prevention of recurrent venous thromboembolism in patients with cancer: a meta-analysis of randomized trials with apixaban. Kardiologiia. 2022;62(3):4-15. (In Russ.).] DOI: 10.18087/cardio.2022.3n1987 33. Wu O, Morris S, Larsen TB, Skjøth F, Evans A, Bowrin K, Wojciechowski P, Margas W, Huelsebeck Ml. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovascular Therapeutics. 2022;2022:2756682. DOI: 10.1155/2022/2756682 34. Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott-Kitslaar DM, Froehling DA, Hodge DO, Peterson LG, Mcbane RD. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. American Journal of Hematology. 2019;94(11):1185-1192. DOI: 10.1002/ajh.25604 35. Computerized Registry of Patients with Venous Thromboembolism (RIETE). Electronic mail: riete@shmedical.es. Accessed 2023 May 03. www.shmedical.es 36. Kearon С, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014;123(12):1794-1801. DOI: 10.1182/blood-2013-12-512681 37. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Координаторы проекта Бокерия Л.А. Затевахин И.И., Кириенко А.И. Флебология. 2015;9(4-2):1-52. [Russian clinical guidelines for diagnosis, treatment and prevention of venous thromboembolic complications. Bokeria LA Zatevakhin II, Kirienko AI, Project coordinators. Flebologiya. 2015;9(4-2):1-52. (In Russ.).] 38. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. The New England Journal of Medicine. 2013;368(8):699-708. DOI: 10.1056/NEJMoa1207541 39. American Society of Hematology 2021 Guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Accessed 2023 May 03. https://ashpublications.org/bloodadvances/article/5/4/927/475194/American-Society-of-Hematology-2021-guidelines-for 40. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Antithrombotic therapy for VTE disease: second Update of the CHEST guideline and Expert Panel report. Chest. 2021;160(6):e545-e608. DOI: 10.1016/j.chest.2021.07.055 41. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Cancer-associated venous thromboembolic disease. Version 1.2020 – 16 April 2020. Accessed 2023 May 03. http://medi-guide.meditool.cn/ymtpdf/9E219C23-6627-2971-9CC9-2BB8D86873AA.pdf 42. RosOncoWeb. Ссылка активна на 03.05.2023. [RosOncoWeb. (In Russ.).] https://www.rosoncoweb.ru/standarts/RUSSCO/2020/2020-47    [ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]